Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
Lebanon Pharmaceuticals And Healthcare
Industry SWOT — 6
Lebanon Political
SWOT — 7
Lebanon Economic SWOT — 8
Lebanon Business Environment SWOT — 9
Pharmaceutical
Business Environment Ratings — 10
Table: Regional Pharma
Business Environment Ratings For Q309 — 10
Limits of
Potential Returns — 11
Risks to Realisation of
Returns — 11
Lebanon – Market
Summary — 13
Regulatory Regime — 15
Public Sector Procurement — 15
Intellectual Property
Regime — 16
IP Shortcomings — 16
Parallel Imports — 17
Counterfeit
Drugs — 18
Free Trade Agreements — 19
Pricing and Reimbursement Issues — 20
Industry
Developments — 22
Epidemiology — 22
HIV/AIDS Infections — 22
Healthcare
Sector — 23
Hospital Sector — 24
Healthcare Insurance — 25
Healthcare Sector
Reforms — 26
Regional
Developments — 27
Pharmaceuticals
Sector — 27
Recent Pharmaceutical Industry
Developments — 28
Research and
Development — 29
Medical Devices — 29
Industry Forecast Scenario — 30
Overall Market
Forecasts — 30
Table: Lebanon – Drug Expenditure
Indicators, 2003-2013 — 31
Key Growth Factors –
Industry — 32
Table: Lebanon – Health Expenditure,
2003-2013 — 32
Key Growth Factors –
Macroeconomic — 33
Table: Lebanon – Economic
Activity, 2006 – 2013 — 35
Prescription Market
Forecast — 36
Table: Lebanon – Prescription Market
Indicators, 2006-2013 (LBPmn unless otherwise
indicated) — 37
OTC Market
Forecast — 38
Table: Lebanon – OTC Market
Indicators, 2003-2013 (LBPmn unless otherwise
indicated) — 39
Patented Drug Market
Forecast — 40
Patented Drug Market
Forecast — 40
Table: Lebanon – Patented Market
Indicators, 2003-2013 — 40
Generics Market
Forecast — 41
Table: Lebanon – Generics Market
Indicators, 2003-2013 — 42
Pharmaceutical Export/Import
Market Forecasts — 43
Table: Lebanon - Pharmaceutical
Export/Import Indicators, 2003-2013 (US$mn) — 43
Other
Healthcare Data Forecasts — 44
Table: Lebanon –
Other Healthcare Data, 2003-2013 — 44
Key Risks to BMI
Forecasts — 45
Competitive
Landscape — 46
Company Profiles — 47
Multinational Companies — 47
Pfizer — 47
Novartis — 48
Merck &
Co — 50
Johnson & Johnson — 52
Sanofi-Aventis — 54
Abbott
Laboratories — 56
Indigenous
Companies — 58
Chalhoub Pharmaceuticals
(CHAPHA) — 58
Alfa Laboratories — 59
Algorithm — 60
Codipha — 61
Country
Snapshot: Lebanon Demographic Data — 62
Section 1:
Population — 62
Table: Demographic Indicators,
2005-2030 — 62
Section 2: Education and
Healthcare — 63
Table: Education,
2002-2005 — 63
Table: Vital Statistics,
2005-2030 — 63
BMI Forecast
Modelling — 64
How We Generate Our Pharmaceutical Industry
Forecasts — 64
Pharmaceutical Business Environment Ratings
Methodology — 65
Ratings Overview — 65
Table: Pharmaceutical Business Environment Indicators — 66
Weighting — 67
Table: Weighting Of
Components — 67
Sources — 67
| 
View Cart
